Cretostimogene Grenadenorepvec
CORE-008
Phase 2 small_molecule active
Quick answer
Cretostimogene Grenadenorepvec for High-Risk Non-Muscle-Invasive Bladder Cancer is a Phase 2 program (small_molecule) at CG Oncology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CG Oncology
- Indication
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active